Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors

            Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors

  PR Newswire

  MUMBAI, February 15, 2013

MUMBAI, February 15, 2013 /PRNewswire/ -- is pleased to announce a new research report on Drivers of M&A
in 2013-2016: PI3Ks and BTK Inhibitors (

New targets/drugs remain an evergreen medical need to address the unmet need
of drug resistance in the treatment of cancer. Large global pharma are
constantly on the hunt for drugs with label expansion potential = Longevity
and Blockbuster Potential! About $10b+ has already been invested in licensing
/acquisition of PI3K and other kinase inhibitors/companies since the last five
years. Scientific data on the role of PI3K, BTK kinase in cancer and clinical
Proof of Concept (PoC) data of the PI3K, BTKs inhibitors have reached a
critical mass and companies with focus in this sector are poised to offer
better treatment options for unmet need in hematologic malignancies. We expect
more acquisitions of the innovator companies and or handsome licensing deals
for unpartnered products as mature data and approvals come in the next few
years. This report highlights the recent progress on the understanding of
PI3Ks/BTK signaling pathway and companies developing PI3K/BTK inhibitors, the
clinical data and competition.

 (Logo: )

Key Points Discussed in the Report

  *Drugs in the pipeline

PI3K inhibitors - Infinity pharma (INFI), Gilead (GILD)

Dual PI3K inhibitor - Onconova/SymBio, Curis (CRIS)

BTK-inhibitors - Safety and clinical efficacy set it apart - Pharmacyclics
(PCYC), Celgene (CELG)

  *M&A in Kinase Inhibitors in the last 5 years
  *Related Milestones/catalysts in 2013-14
  *Combination Studies - PI3K, BTK inhibitors with Rituxan, Bendamustine in
    hematological cancers.
  *Ongoing Clinical Trials of Companies Covered
  *Detailed reports on

SymBio pharma (4582, ¥488)

Curis (CRIS, $2.99)

Gilead (GILD, $40.36)

Pharmacyclics (PCYC, $69.28) -

Infinity pharma (INFI, $35.02)

Request for Sample pages -

Table of Contents

Executive Summary

Drugs in the Pipeline

Phosphoinositide 3-Kinases (PI3Ks) inhibitors

Scientific Rationale

Dual inhibitors

Bruton's Tyrosin Kinase (BTK) Inhibitors

Scientific Rationale

BTK inhibitors - Pipeline

M&A to Follow - Kinase inhibitors have attracted partnering deals at a premium

Kinase Inhibitor: Select M&A / Deals

Upcoming Milestones Related in 2013-14

Combination Studies - PI3K, BTK + Rituxan/ Bendamustine

Idelalisib (GS-1101) - Clinical Data

Rigosertib - Clinical Data

Other PI3K or Dual Inhibitors - Clinical Data

Combination Studies of PI3K and BTK Inhibitors

Ongoing Trials of PI3K and BTK Compounds

Company Analysis

Curis (CRIS) -

Gilead -

Infinity Pharma



Get an overview of the report at or request for sample pages at -

For Complete range of Related Reports:

  *Clinical Trial   -

  *Drugs/Medicines -

  *Pharmaceutical & Healthcare -

  *Inhibitors -

  *Drug Delivery -

About Bharat Book Bureau

Bharat Book Bureau is the leading market research information aggregator that
provides market research reports, industry analysis, company profiles,
business reports, country reports, newsletters and online databases. Our
clients include Corporate, Consulting firms, and Academic Institutions and
Government departments across the globe. Bharat Book Bureau provides over a
million reports from more than 400 publishers around the globe. The market
research reports we provide, help global companies examine the different
markets before setting up a business or expanding into different countries
across the world. They give a complete perspective on the current market
scenario, trends, segments and future outlook.

Contact us: Maria Bharat Book BureauIndia: +91-22-27810772, 27810773USA/Canada
- 1-866-279-8368 (Toll free) Skype - bharatbook E-mail:
Press spacebar to pause and continue. Press esc to stop.